Qomel Company

Qomel Company

TTADAWUL:9600
34.00
SAR
0.00
(0.00%)
350.00MMarket Cap
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
15.07
17.74
18.89
- -
Basic EPS, GAAP
2.51
3.14
2.14
- -
Free Cash Flow per Basic Share
-2.35
-3.4
-3.63
- -
Dividend per Share
0.66
- -
- -
- -
Book Value per Share
6.5
15
17.13
- -
Tangible Book Value per Share
6.49
14.98
17.12
- -
Basic Weighted Avg Shares
7
7
7
7
Sales/Revenue/Turnover
105
124
132
- -
Operating Margin (%)
19.7
22.69
15.88
- -
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
18
22
15
- -
Effective Tax Rate (%)
7.58
8.24
11.89
- -
Profit Margin (%)
16.68
17.68
11.31
- -
Working Capital
36
76
76
69
LT Debt
- -
- -
23
- -
Total Equity
46
105
120
- -
Return on Invested Capital (%)
- -
24.18
12.09
- -
Return on Capital (%)
- -
22.92
11.64
- -
Return on Common Equity (%)
- -
29.18
13.3
- -

Capital Structure

SAR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
31
16
- -
LT Borrowings
25
23
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
420
378
350

Working Capital

SAR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
139
133
133
Cash, Cash Equivalents & STI
34
21
- -
Accounts Receivable, Net
76
78
- -
Inventories
20
19
- -
Total Current Liabilities
60
58
64
Payables & Accruals
- -
- -
- -
ST Debt
31
16
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SAR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
14.21%
Free Cash Flow
- -
- -
6.96%
Net Income, GAAP
- -
- -
-31.87%
Sales/Revenue/Turnover
- -
- -
6.46%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

SAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
124
2025
- -
- -
132
2026
- -
- -
- -

Semi-annual Earnings Per Share

SAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
3.14
2025
- -
- -
2.14
2026
- -
- -
- -

Semi-annual Dividends Per Share

SAR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Hisham Abdullah Mohammed Al-Euqala
Full Time Employees
1,043
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Safwah Commercial Center Riyadh RY Saudi Arabia 11445
IPO Date
May 9, 2024
Website
qomel.com
Business
Qomel Company Limited (9600.SR) operates as a healthcare provider in Saudi Arabia, offering ophthalmology services including vision examination, vision correction and eye surgeries; dental services; wound care services; pharmaceuticals encompassing specialized medications through distribution agreements with multinational companies; and medical supplies and devices. The company maintains headquarters in Riyadh with sales offices and SFDA-compliant warehouses in Jeddah and Dammam, focusing on institutional and government customers across the Kingdom. Founded in 2007, Qomel provides additional healthcare solutions such as pharmacovigilance, regulatory affairs, sales and marketing support; and advances into pharmaceutical manufacturing via its subsidiary Qomel Manufacturing, which secured SAR 50.7 million financing from the Saudi Industrial Development Fund for a new plant targeting specialty products with production slated by end-2025. Recent developments include non-binding memoranda of understanding signed on September 3, 2025, with National Unified Procurement Company (NUPCO) and UK firms Nova Laboratories Limited and Waymade PLC to enhance supply chain efficiency and product registration priority in Saudi Arabia; plus prior June 2025 contracts with NUPCO totaling SAR 30.94 million. Qomel listed shares on the Nomu parallel market and pursues expansion into private sector sales amid growing demand for chronic disease treatments.